The changing landscape of atherosclerosis

P Libby - Nature, 2021 - nature.com
Emerging evidence has spurred a considerable evolution of concepts relating to
atherosclerosis, and has called into question many previous notions. Here I review this …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Clinical review on triglycerides

U Laufs, KG Parhofer, HN Ginsberg… - European heart …, 2020 - academic.oup.com
Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies
have established that triglyceride-rich lipoproteins (TRL) and their remnants as important …

A modern approach to dyslipidemia

AJ Berberich, RA Hegele - Endocrine reviews, 2022 - academic.oup.com
Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

Causes and consequences of hypertriglyceridemia

CJ Packard, J Boren, MR Taskinen - Frontiers in endocrinology, 2020 - frontiersin.org
Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …

[HTML][HTML] Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”

P Moulin, R Dufour, M Averna, M Arca, AB Cefalù… - Atherosclerosis, 2018 - Elsevier
Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by
impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe …

Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol

C Xiao, S Dash, C Morgantini, RA Hegele, GF Lewis - Diabetes, 2016 - Am Diabetes Assoc
Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in
high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid …

A comprehensive update on the chylomicronemia syndrome

RB Goldberg, A Chait - Frontiers in endocrinology, 2020 - frontiersin.org
The chylomicronemia syndrome is characterized by severe hypertriglyceridemia and fasting
chylomicronemia and predisposes affected individuals to acute pancreatitis. When due to …

Role of lipoprotein lipase in lipid metabolism

G Olivecrona - Current opinion in lipidology, 2016 - journals.lww.com
Role of lipoprotein lipase in lipid metabolism : Current Opinion in Lipidology Role of lipoprotein
lipase in lipid metabolism : Current Opinion in Lipidology Log in or Register Subscribe to …

Severe hypertriglyceridemia: existing and emerging therapies

WA Malick, R Do, RS Rosenson - Pharmacology & Therapeutics, 2023 - Elsevier
Severe hypertriglyceridemia (sHTG), defined as a triglyceride (TG) concentration≥ 500
mg/dL (≥ 5.7 mmol/L) is an important risk factor for acute pancreatitis. Although lifestyle …